Welcome to our dedicated page for Phio Pharmaceuticals SEC filings (Ticker: PHIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phio Pharmaceuticals Corp. filings document material events for a clinical-stage siRNA biopharmaceutical company developing INTASYL® gene-silencing therapeutics in immuno-oncology. Recent 8-K disclosures report quarterly and year-end financial results, PH-762 clinical and safety updates, tumor-response data, and development activities for skin cancer indications including cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
The company's regulatory record also covers material agreements and capital-structure matters, including a cGMP drug-product manufacturing services agreement for PH-762 clinical supply and an at-the-market common-stock offering under a shelf registration statement. Governance disclosures include executive employment-agreement amendments and related compensatory arrangements.
Phio Pharmaceuticals Corp. reported that it will present at the H.C. Wainwright 27th Annual Global Investment Conference, which is scheduled for September 8-10, 2025. The company also noted that patients are now being treated in the 5th cohort of its ongoing Phase 1b clinical trial for skin cancer, indicating continued progression of this early-stage study.
Phio Pharmaceuticals Corp. (PHIO) reported interim financials showing continued operating losses and active financing and warrant activity. The company recorded an operating loss of $2,309 and a net loss of $2,166 for the most recent quarter presented, compared with operating loss of $1,914 and net loss of $1,846 in the prior period. Cash flows show a net increase in cash of $5,393 for the period and modest investing outflows.
The filing discloses multiple financings and warrant issuances: net proceeds of approximately $2.646 million from a July 2024 financing, and subsequent registered direct and private placements in January 2025 generating approximately $2.9M, $2.2M, $1.6M and other raises. The company completed a 1-for-9 reverse stock split and recorded significant non-cash equity issuance costs (about $2.4M for warrant fair value and ~$0.2M placement agent warrants). Clinical and collaboration expenses include $4,000,000 incurred for a Phase 1 trial of PH-762. The report lists customary risk factors, reliance on third parties, and material uncertainty around future capital needs.
Phio Pharmaceuticals Corp. (PHIO) filed a Form D announcing a Rule 506(b) private placement that opened 28-Jul-2025.
- Target size: up to $5.08 million in warrants and the underlying common shares.
- Raised to date: $232,149 (≈4.6% of target) from two accredited investors; minimum investment $0.
- Remaining to sell: $4.85 million.
- Broker compensation: $261,753 cash (≈5.2% of capital raised) plus 69,645 warrants (7,500 exercisable at $2.8125; 62,145 at $3.4188).
- Securities offered: options/warrants and the shares issuable upon exercise; no debt or pooled-fund interests.
- Offering duration: expected to close within one year; not linked to a business combination.
- Issuer profile: Delaware-incorporated biotechnology company headquartered in King of Prussia, PA; revenue size undisclosed.
No proceeds are slated for payments to directors, officers or promoters. Reliance on Reg D limits the sale to accredited investors and keeps detailed financials private. Execution risk remains until the full amount is subscribed.
Form 3 Initial Statement of Beneficial Ownership filed by Lisa Cabott Carson for Phio Pharmaceuticals (NASDAQ: PHIO) on June 28, 2025, reporting her beneficial ownership position as of June 6, 2025.
Key details:
- Carson has been appointed as VP, Finance and Administration at Phio Pharmaceuticals
- Currently holds no beneficial ownership of any securities, either direct or indirect
- Filing includes no derivative securities ownership (options, warrants, etc.)
- Individual filing submitted with Power of Attorney documentation (Exhibit 24)
This Form 3 establishes the baseline ownership position for the new officer's future transaction reporting requirements under SEC Section 16(a).